Almost 600 representatives from 25 countries will participate in the fourth edition of the International Congress controlling diabetes and its most severe complications, which will take place in the Varadero spa, from December 7 to 9.
Of the total 300 they are Cuban and have confirmed about 45 international speakers of high level, from practically all the geographical areas of the planet, the Cuban News Agency Iris Lugo, a communication specialist at the Center for Genetic Engineering and Biotechnology (CIGB), which organizes the event.
He said that the representatives of the island come from all work areas in the management of diabetes, which cover the prevention, control and complications of that ailment in the three levels of medical care of the country, primary, secondary and tertiary.
At the appointment, based at the Plaza América Convention Center, the most relevant personalities of the world will attend in the issue of diabetes and, in addition, a United Cuba-United States symposium on that disease that currently affects 422 million people will be carried outon the planet, according to the World Health Organization.
The event includes pre-reresh courses associated with the prevention and management of diabetes, which will take place on December 5 and 6 in the capital and with optional character two workshops: the first aimed at the prevention and control of that condition, with a more endocrine character.
Lugo explained that the second will be dedicated to the management and treatment of diabetic foot ulcers with the use of Heberprot-P®, with a greater profile of angiology and vascular surgery.
In the Cuba Congress, it will show the achievements of the National Program for Integral Diabetes Control, established since 1975, which has 415 clinics in the country and since the 80s of the last century it works in integration with the Cuban biopharmaceutical sector and theMinistry of Public Health.
This has allowed a coordinated work aimed at guaranteeing the most important drug production and equipment for diabetes management.
Heberprot-P® stands out, successful therapy in the treatment of diabetic foot ulcers, developed by CIGB, and which in the last 10 years has allowed to treat 59 thousand Cubans and reduce the relative risk of amputation to less than 29 % ofThe values provided in the event that the therapy was not available, experts clarify.
This has contributed to that annually in Cuba about two thousand 400 diabetic patients retain their limbs.
Applied with satisfactory results to 250 thousand people from 26 countries with that condition, the Heberprot-P® has 20 clinical records granted, said the source.
